Immuno-oncology technology最新文献

{"title":"Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy","authors":"W. den Hartog ,&nbsp;J. Harwood ,&nbsp;S. Kobold","doi":"10.1016/j.iotech.2026.101582","DOIUrl":"10.1016/j.iotech.2026.101582","url":null,"abstract":"<div><div>Chimeric antigen receptor (CAR) cellular therapy, particularly CAR-T cells, has revolutionized the treatment of hematologic malignancies. However, these therapies show limited efficacy against solid tumors, in part due to the inefficient trafficking of effector cells to the tumor. This review explores the potential of engineering natural and synthetic G protein-coupled receptors (GPCRs) to overcome this migratory hurdle. Chemokine receptors have been the most used GPCR family in this setting. Engineering effector immune cells to express chemokine receptors that match tumor-derived chemokines has been shown to increase their chemotaxis and to improve antitumor efficacy in preclinical models. In addition to improved migration, chemokine receptor engineering can also have additional benefits, such as remodeling of the tumor microenvironment and metabolic rewiring of engineered cells. However, the effectiveness of this approach is limited by the tumor-specific and heterogeneous chemokine milieu. Emerging strategies make use of synthetic GPCRs and could overcome some of these limitations using chemogenetic and optogenetic approaches. Here, mutated GPCRs binding only to specific and orthogonal ligands or light-sensitive channels are used for cell modulation and trafficking. Equipping cells with these synthetic GPCRs allows for precise and stimulus-controlled immune cell migration. Together, natural and synthetic GPCR engineering form promising approaches to enhance immune cell trafficking, persistence, and efficacy.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101582"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)","authors":"N. Alshatti ,&nbsp;F. Lemonnier ,&nbsp;E. Bachy ,&nbsp;J. Lopez ,&nbsp;F. Llamas ,&nbsp;D. Damotte ,&nbsp;B. Burron ,&nbsp;Y. Velut ,&nbsp;C. Mauduit ,&nbsp;M. de Charette ,&nbsp;M. Roussel ,&nbsp;X. Palard ,&nbsp;A. Marabelle ,&nbsp;R. Huot","doi":"10.1016/j.iotech.2025.101077","DOIUrl":"10.1016/j.iotech.2025.101077","url":null,"abstract":"<div><h3>Background</h3><div>The efficacy of immune checkpoint blockade therapy requires pre-existing antitumor immunity. Defective antigen presentation during the priming phase can reduce the generation of tumor-specific T cells, which are necessary during the effector phase and subsequent tumor elimination. We propose an <em>in situ</em> immunization strategy to enhance direct tumor antigen presentation by the lymphoma B cells via cluster of differentiation (CD)40 stimulation in order to sensitize B-cell lymphoma to programmed cell death protein 1/programmed death-ligand 1 (PD-L1) blockade therapy.</div></div><div><h3>Materials and methods</h3><div>ITSELF is a multicenter, open-label, dose-escalation phase Ib trial of intratumoral selicrelumab, an agonistic anti-CD40 monoclonal antibody, every 3 weeks for three cycles in combination with intravenous atezolizumab, an antagonistic anti-PD-L1 monoclonal antibody, at 1200 mg every 3 weeks for three cycles followed by intravenous atezolizumab monotherapy for a total of 12 months in patients with relapsed/refractory B-cell lymphoma.</div></div><div><h3>Results</h3><div>Two patients with follicular lymphoma and two patients with diffuse large B-cell lymphoma were enrolled at the first dose level of 1 mg intratumoral selicrelumab. Those four patients received the three cycles of intratumoral selicrelumab in combination with intravenous atezolizumab. Patients did not develop severe adverse events related to the drugs or the intratumoral procedures. No or low-grade adverse events were reported and related to atezolizumab or to the combination therapy. All patients discontinued the treatment because of disease progression according to Lugano 2014 criteria on their first positron emission tomography scan disease evaluation at the end of cycle 3 (week 9). The trial was stopped prematurely because of issues with selicrelumab drug supply.</div></div><div><h3>Conclusion</h3><div>The combination of 1 mg of intratumoral selicrelumab and 1200 mg of intravenous atezolizumab was safe for patients with relapsed/refractory B-cell lymphoma and led to some tumor stabilization or regression, although it did not result in objective tumor response.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101077"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer","authors":"A. Hahn ,&nbsp;S. Irenaeus ,&nbsp;L.C. Sandin ,&nbsp;J. Wenthe ,&nbsp;E. Eriksson ,&nbsp;J.L. Jarblad ,&nbsp;A. Schiza ,&nbsp;H. Dahlstrand ,&nbsp;U. Olsson-Strömberg ,&nbsp;J. Krause ,&nbsp;A. Sundin ,&nbsp;A. Loskog ,&nbsp;G.J. Ullenhag","doi":"10.1016/j.iotech.2026.101585","DOIUrl":"10.1016/j.iotech.2026.101585","url":null,"abstract":"<div><h3>Background</h3><div>LOAd703 is a tumor microenvironment (TME) gene-engineering adenovirus encoding the immunostimulatory transgenes trimerized membrane-bound CD40 ligand (CD40L) and 4-1BB ligand (4-1BBL). Upon administration in the TME, the transgenes are expressed in various cell types to engage both the tumor and its stroma to activate antitumor immunity. CD40–CD40L interaction causes dendritic cell maturation and stimulates T helper 1-type immune responses, whereas 4-1BB–4-1BBL signaling protects T cells and natural killer cells from activation-induced cell death and promotes lymphocyte proliferation. LOAd703 replication with subsequent oncolysis is restricted to cancer cells.</div></div><div><h3>Patients and methods</h3><div>In the dose-escalating part of this clinical study (NCT03225989), LOAd703 was increased according to a standard 3 + 3 design in patients with advanced solid malignancies. LOAd703 was administered every 2 weeks by ultrasound-guided intratumoral injections, combined with a standard-of-care or immune-conditioning gemcitabine-based chemotherapy regimen. The primary endpoint was tolerability.</div></div><div><h3>Results</h3><div>Three dose levels of LOAd703 were evaluated in 10 patients. Treatment was overall safe and well tolerated. The most common side-effects assessed as secondary to LOAd703 were pyrexia, fatigue and headache. All LOAd703-attributed adverse events were of grade 1-2, and the majority were transient and emerged shortly after administration. One patient developed cytokine release syndrome grade 2. The maximum tolerated dose was not reached. Median overall survival was 8.4 months, and the overall response rate was 20%. A trend of higher interferon-gamma (IFN-γ) plasma levels in the highest LOAd703 dose cohort was observed.</div></div><div><h3>Conclusion</h3><div>The acceptable toxicity associated with LOAd703 and chemotherapy, combined with signs of clinical benefit in poor prognostic cancer patients, warrant further studies.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101585"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147396681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","authors":"T. Inthanachai ,&nbsp;C. Sittplangkoon ,&nbsp;H. Tashiro ,&nbsp;S. Yagyu ,&nbsp;T. Palaga ,&nbsp;S. Tawinwung ,&nbsp;K. Suppipat","doi":"10.1016/j.iotech.2026.101584","DOIUrl":"10.1016/j.iotech.2026.101584","url":null,"abstract":"<div><h3>Background</h3><div>Acute myeloid leukemia (AML) is a high-risk malignancy, particularly in patients with primary induction failure or relapsed/refractory disease. CD117 (c-Kit), expressed on both leukemic blasts and normal hematopoietic stem and progenitor cells (HSPCs), represents a potential therapeutic target but poses challenges due to the risk of severe myelotoxicity.</div></div><div><h3>Materials and methods</h3><div>Retrospective flow cytometry analyses of samples from 27 AML patients and AML cell lines were carried out to assess CD117 expression. Second-generation CD117-specific chimeric antigen receptor (CAR) T cells were generated by either retroviral transduction or <em>in vitro</em>-transcribed (IVT) messenger RNA (mRNA) electroporation. The mRNA-based CD117 CAR T cells were evaluated for viability, immunophenotype, cytotoxic activity, and toxicity toward primary HSPCs using clonogenic assays, and compared with retroviral-based counterparts.</div></div><div><h3>Results</h3><div>CD117 was expressed in AML patient samples and cell lines at varying levels. CD117 CAR T cells demonstrated potent and specific cytotoxicity against AML cells. The mRNA-based CAR T cells exhibited high transfection efficiency, good viability, and an immunophenotype similar to non-transduced T cells, and were functionally competent as early as 2 h post-electroporation. In long-term co-culture with a high tumor burden, repeated dosing of mRNA CAR T cells effectively eliminated CD117+ cells, comparable to viral vector-based CAR T cells. Notably, residual mRNA CAR T cells following AML clearance showed no detectable CAR expression and preserved HSPC colony-forming capacity.</div></div><div><h3>Conclusions</h3><div>Our <em>in vitro</em> studies suggest the potential use of mRNA CD117 CAR T cells as a non-genotoxic preconditioning strategy for patients with high-risk or refractory AML.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101584"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147379813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant anti-PD-1 therapy in high-risk cutaneous squamous-cell carcinoma: post hoc insights from the C-POST and KEYNOTE-630 studies","authors":"S. Cavalieri ,&nbsp;A. Ottini ,&nbsp;C. Bergamini ,&nbsp;S. Alfieri ,&nbsp;I. Nuzzolese ,&nbsp;E. Colombo ,&nbsp;B. Lombardi Stocchetti ,&nbsp;L. Licitra","doi":"10.1016/j.iotech.2025.101557","DOIUrl":"10.1016/j.iotech.2025.101557","url":null,"abstract":"<div><h3>Background</h3><div>Cutaneous squamous-cell carcinoma (cSCC) is cured with surgery with or without radiotherapy in most cases, but patients with high-risk features remain prone to recurrence. Until recently, no systemic adjuvant therapy was available. Recently, two phase III trials assessed post-operative anti-programmed cell death protein 1 (PD-1): C-POST (cemiplimab), which met its primary endpoint, and KEYNOTE-630 (pembrolizumab), which did not.</div></div><div><h3>Methods</h3><div>We compared the eligibility criteria and risk definitions of both trials. Published disease-free survival (DFS) curves were digitized, and individual patient data (IPD) were reconstructed with validated algorithms. DFS was analyzed using Kaplan–Meier estimates, log-rank tests, Cox models, and restricted mean survival time. Subgroup analyses considered nodal high-risk patients in the two studies. Hazard ratios (HRs) informed a meta-analysis with the generic inverse variance method.</div></div><div><h3>Results</h3><div>The placebo arms showed no DFS difference. Although no direct comparisons can be made across trials and in spite of the different eligibility criteria of the two studies, cemiplimab achieved superior DFS versus pembrolizumab. Pooling experimental arms confirmed a DFS benefit with PD-1 therapy [HR 0.53, 95% confidence interval (CI) 0.40-0.71]. Cemiplimab (HR 0.36) and pembrolizumab (HR 0.44) consistently reduced recurrence risk in nodal high-risk patients, yielding a combined HR of 0.40 (95% CI 0.26-0.62) with no heterogeneity.</div></div><div><h3>Conclusion</h3><div>Adjuvant PD-1 blockade significantly improves DFS in high-risk cSCC. With the caveats of indirect comparisons and the pending full publication of one of the two trials, these post hoc findings are hypothesis generating and may help inform the selection of high-risk patients deserving adjuvant therapy.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101557"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma","authors":"T.J. Monberg ,&nbsp;S.A. Tvingsholm ,&nbsp;M. Svensson-Frej ,&nbsp;C. Vestergaard ,&nbsp;M. Ormhøj ,&nbsp;J.W. Kjeldsen ,&nbsp;T.H. Borch ,&nbsp;R.B. Holmstroem ,&nbsp;N. Jayashankar ,&nbsp;J.S. Granhøj ,&nbsp;A.R. Cordt ,&nbsp;S.K. Larsen ,&nbsp;Ö. Met ,&nbsp;S.R. Hadrup ,&nbsp;I.M. Svane","doi":"10.1016/j.iotech.2025.101581","DOIUrl":"10.1016/j.iotech.2025.101581","url":null,"abstract":"<div><h3>Background</h3><div>Tumor-infiltrating lymphocyte (TIL) therapy is effective in metastatic melanoma (MM), but the need for resectable tumor tissue limits its accessibility. Antigen-presenting scaffolds (Ag-scaffolds) constitute a technology developed for the specific expansion of tumor-associated antigen (TAA)-specific T cells directly from peripheral blood. Ag-scaffolds are built on a dextran backbone with coattached interleukin 2 (IL-2), interleukin 21 (IL-21), and major histocompatibility complex class I molecules loaded with the top 30 most frequently expressed TAAs in MM patients. The resulting multiple antigen-specific endogenously derived T-cell (MASE-T) infusion product is enriched for CD8+ TAA-specific T cells. We hypothesize that treatment with MASE-T therapy is safe and feasible in patients with immune checkpoint inhibitor (ICI)-resistant MM.</div></div><div><h3>Patients and methods</h3><div>In this phase I, first-in-human, clinical trial (NCT04904185), six patients with ICI-resistant MM received MASE-T therapy preceded by 3 days of lymphodepleting chemotherapy with cyclophosphamide and fludarabine phosphate. The primary endpoint was the safety and feasibility of the treatment.</div></div><div><h3>Results</h3><div>MASE-T cells were successfully expanded in 88% (7/8) of the included patients, and most MASE-T products were enriched for T-cell populations targeting multiple TAAs. Administration of MASE-T therapy was safe with no MASE-T-related toxicities. Clinical efficacy was limited, with 3 out of 6 (50%) patients having stable disease 6 weeks after treatment.</div></div><div><h3>Conclusions</h3><div>This trial demonstrates that Ag-scaffold-driven expansion of TAA-specific T cells from the peripheral blood of patients with MM is feasible, and the resulting MASE-T infusion product can be safely administered. However, further development is required to unleash the full potential of this technology.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101581"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145927086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care","authors":"E. Bengala ,&nbsp;D. Santini ,&nbsp;V. Picone","doi":"10.1016/j.iotech.2025.101558","DOIUrl":"10.1016/j.iotech.2025.101558","url":null,"abstract":"<div><h3>Background</h3><div>The combination of botensilimab + balstilimab demonstrated promising clinical activity in heavily pre-treated patients with microsatellite-stable metastatic colorectal cancer (mCRC) in a recently published phase I study (NCT03860272).</div></div><div><h3>Patients and methods</h3><div>Our objective was to derive overall survival (OS), progression-free survival (PFS) and safety data from the trials of reference of the current standard of care for refractory mCRC and from the above-mentioned study, and to compare them. After a systematic search of PubMed, we selected four studies (SUNLIGHT, FRESCO-2, RECOURSE, CORRECT). Individual patient OS and PFS data were extracted from Kaplan–Meier curves and more frequent toxic effect rates were collected.</div></div><div><h3>Results</h3><div>Immunotherapy showed higher efficacy in terms of median OS both compared with trifluridine-tipiracil plus bevacizumab [hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.44-0.89] and to later lines of treatment: fruquintinib, regorafenib, and trifluridine-tipiracil alone. These results were confirmed by median PFS comparison of all the therapies except for the trifluridine-tipiracil + bevacizumab combination (HR 0.46, 95% CI 0.35-0.61 in favor of trifluridine-tipiracil + bevacizumab). As for treatment-related adverse events the most frequent with immunotherapy were fatigue and diarrhea. The other regimens were associated with hematologic toxic effects, nausea, hypertension, and dermatological toxicity.</div></div><div><h3>Conclusion</h3><div>These findings suggest that the immunotherapy combination appears to be a potential option for patients with refractory mCRC while being associated with a completely different toxicity profile. However, confirmation of its efficacy awaits the results of randomized studies. Better comprehension of disease characteristics related to treatment response, such as metastatic sites and molecular biology, is warranted for patient selection.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101558"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145754168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis","authors":"S. Haider ,&nbsp;M. Hong ,&nbsp;J. Descallar ,&nbsp;B. Balakrishnar ,&nbsp;T.L. Roberts ,&nbsp;K. Keat ,&nbsp;W. Chua","doi":"10.1016/j.iotech.2025.101559","DOIUrl":"10.1016/j.iotech.2025.101559","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma patients with pre-existing autoimmune diseases (AIDs) have been excluded from clinical trials of immune checkpoint inhibitors (ICIs), due to a risk of flare and immune-related adverse effects (irAEs).</div></div><div><h3>Materials and methods</h3><div>A comprehensive literature search of Medline, Embase, CINAHL and Scopus was carried out. Studies of melanoma patients with pre-existing AIDs were included. Two reviewers used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Outcomes assessed included all-grade and grade 3 or 4 <em>de novo</em> irAEs, AID flare, treatment discontinuation owing to adverse effect(s), treatment-related mortality and objective response rate (ORR).</div></div><div><h3>Results</h3><div>Thirty-two percent of patients with AIDs developed a flare, with 80% requiring immunosuppression. In patients with AIDs, meta-analysis revealed a higher risk of all-grade irAEs [risk ratio (RR) 1.16, 95% confidence interval (CI) 1.01-1.33, <em>P</em> = 0.0106] but not grade 3 or 4 (RR 1.21, 95% CI 0.99-1.47, <em>P</em> = 0.0663). Treatment discontinuation, treatment-related mortality and ORR were not different among patients with AIDs.</div></div><div><h3>Conclusions</h3><div>Melanoma patients with pre-existing AIDs are at significant risk of flare with ICI use. These patients had an increased risk of irAEs of any grade. Although there was a trend towards increased risk of severe irAEs, this was not statistically significant. irAEs did not result in treatment-related deaths, and there were no differences in treatment response. Risks should be discussed, coupled with close monitoring.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"29 ","pages":"Article 101559"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146037730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"75eTiP PerceIVe: Power of liquid biopsy tracking in immunotherapy treated unresectable stage III and stage IV melanoma","authors":"A. Javaid ,&nbsp;S. Cheruvu ,&nbsp;P.G. Corrie ,&nbsp;K. Edmonds ,&nbsp;A. Laing ,&nbsp;J. Larkin ,&nbsp;R. Lee ,&nbsp;R. Mair ,&nbsp;A. Modi ,&nbsp;F. Mouliere ,&nbsp;A. Murra ,&nbsp;J. Pozas Perez ,&nbsp;A. Roshan ,&nbsp;D. Rothwell ,&nbsp;M. Wheater ,&nbsp;K. Young","doi":"10.1016/j.iotech.2025.101158","DOIUrl":"10.1016/j.iotech.2025.101158","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101158"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"29P Circulated T cell exhausted subtypes and immunosuppressive tregs predict response in CRC patients","authors":"A. Xagara ,&nbsp;K.P. Efraimidi ,&nbsp;K. Vasilieva ,&nbsp;E. Chantzara ,&nbsp;I. Samaras ,&nbsp;V.N. Papadopoulos ,&nbsp;A. Kotsakis","doi":"10.1016/j.iotech.2025.101112","DOIUrl":"10.1016/j.iotech.2025.101112","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101112"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}